We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+19.84%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.88B
AUM Growth
+$360M
Cap. Flow
+$23.1M
Cap. Flow %
0.8%
Top 10 Hldgs %
84.68%
Holding
41
New
2
Increased
5
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
OBSV
ObsEva SA Ordinary Shares
OBSV
+$41M
2
CASC
Cascadian Therapeutics, Inc.
CASC
+$30.6M
3
ADAP
Adaptimmune Therapeutics
ADAP
+$9.38M
4
AFMD
Affimed
AFMD
+$8.55M
5
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$4.33M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$50.6M
2
GRPN icon
Groupon
GRPN
+$19.3M
3
HIVE
Aerohive Networks
HIVE
+$1.83M
4
ZSAN
Zosano Pharma Corporation
ZSAN
+$1.6M
5
AGRX
Agile Therapeutics
AGRX
+$761K

Sector Composition

Rank Sector Weight
1 Healthcare 86.21%
2 Communication Services 2.06%
3 Consumer Discretionary 1.42%
4 Technology 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$1.58B 54.99%
10,275,113
– –
ARDX icon
2
Ardelyx
ARDX
$1.24B
$178M 6.2%
14,083,582
– –
AKAO
3
DELISTED
Achaogen Inc
AKAO
$132M 4.58%
5,215,128
+3
+0% +$62
DERM
4
DELISTED
Dermira, Inc.
DERM
$120M 4.16%
3,506,649
– –
EPZM
5
DELISTED
Epizyme, Inc
EPZM
$107M 3.73%
6,260,851
– –
RARX
6
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$74.4M 2.59%
3,493,636
– –
CRSP icon
7
CRISPR Therapeutics
CRSP
$4.65B
$70.1M 2.44%
3,220,728
– –
ADAP
8
DELISTED
Adaptimmune Therapeutics
ADAP
$66.3M 2.3%
12,025,999
+2,145,000
+22% +$9.38M
GRPN icon
9
Groupon
GRPN
$1.05B
$59.2M 2.06%
752,841
-250,947
-25% -$19.3M
SENS icon
10
Senseonics Holdings Inc
SENS
$255M
$47.1M 1.64%
1,315,264
– –
CBIO
11
Crescent Biopharma
CBIO
$598M
$46.6M 1.62%
85,841
– –
CRCM
12
DELISTED
CARE.COM, INC.
CRCM
$40.8M 1.42%
3,260,989
– –
CASC
13
DELISTED
Cascadian Therapeutics, Inc.
CASC
$37.5M 1.31%
9,064,575
+7,272,909
+406% +$30.6M
AUPH icon
14
Aurinia Pharmaceuticals
AUPH
$1.92B
$35.3M 1.23%
4,808,483
+740,740
+18% +$3.42M
OBSV
15
DELISTED
ObsEva SA Ordinary Shares
OBSV
$34.7M 1.21%
+3,336,563
New +$41M
LXRX icon
16
Lexicon Pharmaceuticals
LXRX
$1.03B
$34.2M 1.19%
2,382,286
– –
NVRO
17
DELISTED
NEVRO CORP.
NVRO
$33.7M 1.17%
359,678
– –
KA
18
DELISTED
Kineta, Inc. Common Stock
KA
$27.8M 0.97%
25,406
– –
SBBP
19
DELISTED
Strongbridge Biopharma plc.
SBBP
$19.7M 0.68%
4,141,308
– –
HIVE
20
DELISTED
Aerohive Networks
HIVE
$18.1M 0.63%
4,309,691
-363,845
-8% -$1.83M
ELGX
21
DELISTED
Endologix Inc
ELGX
$18M 0.63%
249,020
– –
TRVN
22
DELISTED
Trevena, Inc.
TRVN
$14M 0.49%
6,099
– –
RIGL icon
23
Rigel Pharmaceuticals
RIGL
$709M
$10.4M 0.36%
324,315
– –
TCON
24
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$10.3M 0.36%
13,796
– –
AVEO
25
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$9.65M 0.34%
1,636,269
+600,000
+58% +$4.33M
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q1 2017 Portfolio in Review

As of Q1 2017, NEA Management Company held 41 positions worth $2.88B, up 14% from $2.51B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

NEA Management Company's Q1 2017 filing shows 2 new, 5 increased, 3 reduced and 3 closed positions. Its largest new stake was ObsEva SA Ordinary Shares: 3,336,563 shares worth $34.7M. The largest sale was Clovis Oncology, Inc., an estimated $50.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Communication Services and Consumer Discretionary.

  • NEA Management Company's largest Q1 2017 buy was ObsEva SA Ordinary Shares: 3,336,563 shares worth $34.7M.
  • NEA Management Company added most to Cascadian Therapeutics, Inc. in Q1 2017, an estimated $30.6M increase.
  • NEA Management Company's biggest Q1 2017 reduction was Groupon, cutting an estimated $19.3M.
  • NEA Management Company fully exited Clovis Oncology, Inc. in Q1 2017, selling an estimated $50.6M.
  • NEA Management Company's ten largest holdings make up 85% of its $2.88B portfolio in Q1 2017.
  • NEA Management Company opened 2 new positions and closed 3 in Q1 2017.
  • NEA Management Company's portfolio value rose 14% quarter-over-quarter to $2.88B.

Based on NEA Management Company's 13F filing for Q1 2017, filed 10 May 2017.